Close
Patheon

News Releases

  • 16 Mar 2017

    Highlights:

    • 1Q 2017 revenue increased by 13% year-over-year to $457M
    • Net income from continuing operations was $28M
      • Net income from continuing operations per diluted share was $0.19
    • 1Q 2017 Adjusted EBITDA was $83M, or 18% of revenue, a 350 bp year-over-year improvement
    • Adjusted net income from continuing operations was $21M
      • Adjusted net income from continuing operations per diluted share was $0.14
    • Updated financial outlook for fiscal year 2017
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended January 31, 2017. First quarter 2017 revenue was $457 million, an increase of 13% compared to the first quarter of 2016. Adjusted EBITDA in the first quarter was $83 million, 40% higher than the prior-year period. Adjusted EBITDA margin as a percentage of revenue was 18%,more...
  • 03 Mar 2017
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today announced that it will release financial results for the first fiscal quarter 2017 on Thursday, March 16, 2017 before the market opens. Patheon’s management – Jim Mullen, CEO; Michel Lagarde, President; and Stuart Grant, CFO, will host a conference call and webcast to discuss the results on Thursday, March 16, 2017 at 8:more...
  • 02 Mar 2017
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that the company was selected as the winner of the “Supply Chain Resiliency Partner of the Year” award by the Global Supply Chain Resiliency Council. The award was presented at RESILIENCE 2017, the Annual Global Supply Chain Resiliency Council Conference and Awards Gala onmore...